Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
about
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United KingdomPazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.
P2860
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of pazopani ...... renal cell carcinoma in Canada
@en
Cost-effectiveness of pazopani ...... enal cell carcinoma in Canada.
@nl
type
label
Cost-effectiveness of pazopani ...... renal cell carcinoma in Canada
@en
Cost-effectiveness of pazopani ...... enal cell carcinoma in Canada.
@nl
prefLabel
Cost-effectiveness of pazopani ...... renal cell carcinoma in Canada
@en
Cost-effectiveness of pazopani ...... enal cell carcinoma in Canada.
@nl
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of pazopani ...... renal cell carcinoma in Canada
@en
P2093
P2860
P304
P356
10.3747/CO.23.2244
P577
2016-08-12T00:00:00Z